Showing 6 results for Glibenclamide
Mahnaz Lankarani, Fatemeh Bandarian, Ozra Tabatabaei, Mohammad Pajouhi, Bagher Larijani,
Volume 4, Issue 1 (7-2004)
Abstract
Background: Gliclazide is a second generation sulfonylurea which its efficacy and safety in the treatment of diabetes has been established. Diamicron MR (30 mg) is a new formulation of gliclazide with modified release which offer once daily dosage administration. This study was designed to assess the effect of combination therapy with diamicron and metformin in the treatment of type 2 diabetes.
Methods: 16 patients with type 2 diabetes (2 males, 14 females) more than 35 years old who despite treatment with glibenclamide and metformin had poor diabetes control participated in this clinical trial.HbA1c, lipid profile, liver and renal function tests at the end of study were compared with before.
Results: No significant changes was found in FBS, BS2hpp, lipid profile and renal and liver function tests at the end of study. Patients' weight was stable during the study.
Conclusion: Regardless of well efficacy of diamicron in the treatment of new diabetics cases, it is not recommended for patients with poor diabetes control despite of combination therapy with metformin and glibenclamide.
Gholam Hossein Ranjbar Omrani, Omid Bazargan Lari, Ali Reza Mehdizadeh, Najaf Zare, Nika Saadat,
Volume 4, Issue 2 (8-2004)
Abstract
Background: Diabetes mellitus is the most common cause of renal failure, blindness, non- traumatic amputation and neuropathy. Homocysteine, a sulfurated amino acid, has a close correlation with Methionine and Cysteine. The conversion of Methionine to Homocysteine and Cysteine is required coenzymes like vitamin B6, B12 and Folate. The effect of Metformin on serum Homocysteine level by decreasing vitamin B12 level in patients with type 2 diabetes mellitus was described previously. Methods: This is a prospective clinical trail study among patients with type 2 diabetes mellitus in Shiraz. 76 patients were divided into two groups (38 patients in each group). First group treated with Metformin 500-2000 mg/day and the second group treated with Glibenclamide 5-20 mg/day with follow up period of at least 6 months. Hb and MCV were used in follow up to detect megaloblastic anemia, indicator of B12 and folate deficiency. Fasting plasma Homocysteine level Hb A1C and blood sugar were measured in baseline and at 3 and 6 months follow up periods.
Results: There was no significant difference between age, sex, weight, height and BMI and baseline serum profile between the two groups. Homocysteine level increased significantly in Metformin group at 3 and 6 months(P=0.003 and 0.001 respectively). Mean plasma homocysteine level after 6 months were 10.98±0.58 μmol/l in Metformin and 10.0± 0.88 μmol/l in Glibenclamide group, with significant difference between the two groups (P=0.001).
Conclusion: Metformin increases the plasma Homocysteine level. Metformin will accumulate highly in gastrointestinal wall and cause malabsorption of vitamin B12, therefore we can conclude that the use of Metformin for 6 months can cause vitamin B12 malabsorption and increase in plasma homocysteine level. Increase in plasma homocysteine level was 7.54% in our study that is higher in comparing to the other studies. It can be explained by longer duration of Metformin therapy in our study. Rising in Homocysteine levels may have detrimental effect on vessels that need further study.
Homeira Zardouz, Saleh Zahedi Asl, Mohammad Kazem Gharib Naseri,
Volume 5, Issue 4 (6-2006)
Abstract
Background: Regarding the adverse effect of stress on glycemic control in type 2 diabetic patients, the present study investigates the function of Glibenclamide on insulin release from β cells of rat pancreatic islets, subsequent to chronic psychological stress exposure.
Methods: In this study 30 male Wistar rats were divided into equal groups of control and experiment (5 groups). Four different restraint stressors with random sequence were used 1h twice daily for 15 and 30 days. 24 hours after the last stress session, static insulin secretion from isolated pancreatic islets of each animal were evaluated in the presence of 5.6, 8.3 and 16.7 mM glucose. Also insulin release in response to 5.6 mM glucose in the presence of 10 μM Glibenclamide was evaluated.
Results: The insulin release from isolated islets of the stress experienced animals was significantly increased only on the 30th day as compared to the control animals. In the experiment group, insulin release from the islets in the presence of 5.6 mM glucose alone was significantly increased on the 15th and 30th days as compared to the first day. However, in the control group there was no significant increase in insulin release at the similar conditions. In contrast to the control group, insulin release in response to 5.6 mM glucose in the presence of 10 μM Glibenclamide revealed no significant difference in the experiment group on the 1st 15th and 30th days as compared to the insulin release in the presence of 5.6 mM glucose alone. Insulin release from the isolated islets exposed to 5.6 mM glucose in the presence of 10 μM Glibenclamide, on different experimental days was not significantly different between the control and experiment groups.
Conclusion: According to the results of this study, it appears that chronic psychological stress decreases the responsiveness of pancreatic β cells to Glibenclamide, subsequently could prevent the augmentation of insulin release induced by the drug. This finding is worthy to consider in metabolic control of diabetic patients whom consume the agent.
Mahmood Khayatian, Bagher Larijani, Bijan Farzami, Shirin Pournourmohammadi, Hoda Boushehri,
Volume 6, Issue 1 (8-2006)
Abstract
Background: Sulfonylurea agents such as Glibenclamide (Glyburide) have been widely prescribe in treatment of type 2 diabetic patients for decades, but controversy remains about their precise mechanism of action. On the other hand, glucokinase serves as a glucose sensor in pancreatic β-cells and plays a key role in the regulation of insulin secretion and glucose homeostasis. The aim of the present study was to evaluate the effect of Glibenclamide on insulin secretion and glucokinase activity in the rat isolated pancreatic islets of Langerhans.
Methods: The islets from normal and type 2 diabetic rats were isolated by collagenase digestion method. Glucokinase activity was measured via determination the rate of glucose-6-phosphate formation in the fluorometric assay. Insulin secretion from hand-picked islets was evaluated by static incubation technique. Insulin concentration was measured by rat insulin ELISA kit.
Results: Our findings obtained from incubation of Glybenclamide with pancreatic islets revealed that this agent increases basal insulin secretion (at 2.8 mM glucose) in both normal and diabetic rats as compared it with control islet (without drug). However, the increase of insulin secretion in response to 16.7 mM glucose was not significant. On the other hand, Glybenclamide had no activating and/or inhibiting effect on pancreatic glucokinase activity in both diabetic and normal Rats. But reduced activity of this enzyme in diabetic rats was significant in comparison with normal.
Conclusion: These data show that increasing effect of Glybenclamide on insulin secretion is through a mechanism other than affecting Glucose Mediated Insulin Release. Moreover, the regulation of pancreatic glucokinase does not depend on glybenclamid.
Nargol Ahmadi Mahmoodabadi, Hossein Madani, Parvin Mahzooni, Akbar Vahdati,
Volume 6, Issue 1 (8-2006)
Abstract
Background: Artichoke with the scientific name of Cynara scolymuse is a plant from compositae family. In this research, the effect of hydro alcoholic artichoke extract on serum glucose, lipids and lipoproteins and prevention of type 1 diabetes mellitus was investigated.
Methods: Twenty mature male Rats with mean weight of 200-250 gr in four groups were arranged. Rats in the control group, received physiological serum. The Second group (diabetic) received 120 mg/kgbw Alloxan monohydrate. The Third group (diabetic + Glibenclamide) received 0.5 mg/kgbw Glibenclamide in addition of the similar treatment with second group. The Fourth group (Alloxan monohydrate + Cynara scolymus), received 120 mg/kgbw Alloxan monohydrate with 300 mg/kgbw of Cynara scolymus simultaneously. Prescribing materials in all groups was done as interaperitoneal injection(IP). Fourty eight hours after last IP, blood sample was taken from each animal via cardiac puncture to measure blood factors.
Results: The results indicated significant reduction in glucose, cholesterol, triglyceride, VLDL and LDL levels in the treated group with extract and Alloxan monohydrate simultaneously as to compared diabetic group. Also, the result indicated significant increase in HDL level. Hydroalcoholic Artichoke extract could not reduce blood glucose level as compared with Glibenclamide, but had similar effects on other factors in comparison with Glibenclomide.
Conclusion: Artichoke contains antioxidants compounds, that plays a protective role on beta cells against Alloxan. The results of this research indicate that hydro alcoholic extract of Cynara scolymus could effectively prevent type 1 diabetes mellitus.
Mohammad Ali Sardar, Ali Akbar Shamsian, Morteza Taghavi,
Volume 6, Issue 1 (8-2006)
Abstract
Background: Combination of physical activity and pharmacotherapy in diabetes may augment the effects of the drug and may allow lower doses of medication that can minimize the side effects. The goal of the study was to determine the effectiveness of aerobic training and Glibenclamide combination in type 2 diabetes.
Methods: A total of 28 men with type 2 diabetes were divided to 3 groups randomly: Glibenclamide (5 mg daily) only, Glibenclamide (5 mg daily) plus aerobic training, Glibenclamide (2.5 mg daily) plus aerobic training. Aerobic training protocol was performed for 12 week, 3 days (session) a week, 45 minutes in a session (ergo cycle program at 60-70 % heart rate reserve). Fasting glucose, HbA1c, fasting insulin, c-peptide, and insulin resistance were measured at pre, mid and post treatment periods. Analysis of Variance test (ANOVA) were used to evaluate data.
Results: HbA1c significantly decreased and c-peptide significantly increased in three groups (P<0.05).There were also no between-group differences for c-peptide and HbA1c (P>0.05). Fasting insulin concentration did not alter in three groups, however, insulin resistance decreased ( no significant ) after 12 weeks.
Conclusion: In type 2 diabetic patients, Glibenclamide treatment alone or combination of aerobic training and Glibenclamide treatment, was effective in improving glycemic control in patients with type 2 diabetes .As a result, in patients with type 2 diabetes, the addition of aerobic training to Glibencelamide treatment allow lower doses of Glibenclamide to be used without impairment in glycemic control.
